Navigation Links
Victhom to Participate in the OneMedPlace Finance Forum
Date:1/7/2009

QUEBEC, Jan. 7 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA on January 13 and 14, 2009. Nader Kameli, Chief Operating Officer of Victhom's Neurobionix division, will be presenting on Tuesday, January 13 at 9:00 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell Street. Information about the OneMedPlace Finance Forum may be found at http://www.onemedplace.com.

Victhom has developed the Neurostep(R) System, an implantable neurostimulation device designed to restore mobility and independence for patients with partial paralysis of the leg as a result of hemiparetic stroke. The Neurostep(R) System has been engineered to integrate with the body's natural sensing and stimulation network and designed to closely mimic specific functions that have been interrupted or lost due to disease or injury. The Neurostep(R) is an investigational medical device currently in human clinical study in four clinical sites outside U.S. and is planned for market introduction in Europe late 2009.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.

About OneMedPlace

OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
2. Rigel to Participate at the RBC Capital Markets Healthcare Conference
3. Boston Scientific to Participate in Piper Jaffray Health Care Conference
4. B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit
5. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
6. Sinovac to Participate in Two Upcoming Investor Conferences
7. Endovascular Forum Inc.s President to Participate in Health 2.0 Northeast Panel
8. Boston Scientific to Participate in UBS Global Life Sciences Conference
9. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
10. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
11. Pittsburgh Region Middle School Students Participate in Hands-on Tissue Engineering Summer Camp
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. ... “As we seek to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease ...
(Date:3/27/2017)... March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ROKA), ... for the detection of foodborne pathogens,  today announced that ... Company Spring 2017 Convention on March 29 at 9:50am ET. ... Marquis. About Roka Bioscience ... Roka Bioscience is ...
(Date:3/27/2017)... Properties (NYSE: CUZ ) announced today that Amgen, ... 10-year, approximately 125,000 square-foot lease at Corporate Center, a 1,224,000 ... submarket of Tampa, FL. ... for their new location in Tampa ," ... of Cousins Properties. "Amgen is a cutting-edge global company at ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
Breaking Biology Technology:
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader ... its elite iris biometric solution on the latest ... LTE at Mobile World Congress 2017 (February ... Booth in Hall 3, Stand 3E10. ... Qualcomm Haven™ security platform—a combination of hardware, ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):